ALK Abelló, based in Denmark, is a global pharmaceutical company specializing in the field of allergy immunotherapy. The company was founded in 1923 by Dr. Kåre Nørgaard Abell, a Danish immunologist.

ALK Abelló has its headquarters in Hørsholm, Denmark. The company's main focus is on the development, manufacture, and distribution of allergy vaccines. These vaccines are designed to treat and prevent allergies caused by a variety of allergens, such as pollen, house dust mites, and pet dander.

ALK Abelló's flagship product is its sublingual allergy immunotherapy tablet, known as Grazax, which is prescribed to patients suffering from grass pollen allergies. In addition to its headquarters in Denmark, ALK Abelló operates globally with subsidiaries and joint ventures in over 30 countries. Some of its noteworthy subsidiaries include ALK-Abelló Asia Pacific Ltd., ALK Abelló Benelux B.

V., and ALK Abelló Mexico S. A. The company has also formed strategic partnerships with various healthcare organizations and research institutions to further its research and development efforts.

ALK Abelló holds a strong market position in the global allergy immunotherapy market. The company's products are widely recognized for their effectiveness and safety. It competes with other pharmaceutical companies in the allergy immunotherapy space such as Stallergenes Greer, Allergy Therapeutics, and Anergis.

In terms of global sales, ALK Abelló has consistently reported strong financial performance. The company's revenue has been growing steadily, thanks to its expanding product portfolio and geographical presence. ALK Abelló has made significant investments in research and development, leading to the introduction of innovative products and improvements in existing treatments.

One notable achievement of ALK Abelló was the launch of its tablet-based allergy immunotherapy product, Grazax, which revolutionized the field of allergy treatment. The company continues to innovate and expand its product offerings to cater to a diverse range of allergies. As of the latest updates, ALK Abelló continues to focus on research and development to enhance its product portfolio.

The company is dedicated to improving the lives of allergy sufferers worldwide and remains at the forefront of developing effective and safe allergy immunotherapy treatments